229 related articles for article (PubMed ID: 15750152)
21. Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma.
Pöpperl G; Götz C; Rachinger W; Gildehaus FJ; Tonn JC; Tatsch K
Eur J Nucl Med Mol Imaging; 2004 Nov; 31(11):1464-70. PubMed ID: 15248032
[TBL] [Abstract][Full Text] [Related]
22. 18F-AFETP, 18F-FET, and 18F-FDG imaging of mouse DBT gliomas.
Sai KK; Huang C; Yuan L; Zhou D; Piwnica-Worms D; Garbow JR; Engelbach JA; Mach RH; Rich KM; McConathy J
J Nucl Med; 2013 Jul; 54(7):1120-6. PubMed ID: 23650628
[TBL] [Abstract][Full Text] [Related]
23. Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour.
Lau EW; Drummond KJ; Ware RE; Drummond E; Hogg A; Ryan G; Grigg A; Callahan J; Hicks RJ
J Clin Neurosci; 2010 Jan; 17(1):43-9. PubMed ID: 20004582
[TBL] [Abstract][Full Text] [Related]
24. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas.
Pauleit D; Floeth F; Hamacher K; Riemenschneider MJ; Reifenberger G; Müller HW; Zilles K; Coenen HH; Langen KJ
Brain; 2005 Mar; 128(Pt 3):678-87. PubMed ID: 15689365
[TBL] [Abstract][Full Text] [Related]
25. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of gliomas located in the brainstem and spinal cord.
Tscherpel C; Dunkl V; Ceccon G; Stoffels G; Judov N; Rapp M; Meyer PT; Kops ER; Ermert J; Fink GR; Shah NJ; Langen KJ; Galldiks N
Neuro Oncol; 2017 May; 19(5):710-718. PubMed ID: 28039366
[TBL] [Abstract][Full Text] [Related]
26. Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG.
Cook GJ; Houston S; Barrington SF; Fogelman I
J Nucl Med; 1998 Jan; 39(1):99-103. PubMed ID: 9443745
[TBL] [Abstract][Full Text] [Related]
27. Epileptic Activity Increases Cerebral Amino Acid Transport Assessed by 18F-Fluoroethyl-l-Tyrosine Amino Acid PET: A Potential Brain Tumor Mimic.
Hutterer M; Ebner Y; Riemenschneider MJ; Willuweit A; McCoy M; Egger B; Schröder M; Wendl C; Hellwig D; Grosse J; Menhart K; Proescholdt M; Fritsch B; Urbach H; Stockhammer G; Roelcke U; Galldiks N; Meyer PT; Langen KJ; Hau P; Trinka E
J Nucl Med; 2017 Jan; 58(1):129-137. PubMed ID: 27469356
[TBL] [Abstract][Full Text] [Related]
28. Low efficacy of 18F-FDG PET for detection of uveal malignant melanoma compared with 123I-IMP SPECT.
Kato K; Kubota T; Ikeda M; Tadokoro M; Abe S; Nakano S; Nishino M; Kobayashi H; Ishigaki T
J Nucl Med; 2006 Mar; 47(3):404-9. PubMed ID: 16513608
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods.
Kresnik E; Mikosch P; Gallowitsch HJ; Kogler D; Wiesser S; Heinisch M; Unterweger O; Raunik W; Kumnig G; Gomez I; Grünbacher G; Lind P
Eur J Nucl Med; 2001 Jul; 28(7):816-21. PubMed ID: 11504077
[TBL] [Abstract][Full Text] [Related]
30. [Fluoroethylthyrosine 18F PET in the detection of brain tumours].
Nataf V; Kerrou K; Balogova S; Pene F; Huchet V; Gutman F; Prignon A; Muresan IP; Giannesini C; Izrael V; Schlienger M; Talbot JN
Bull Cancer; 2010 May; 97(5):495-506. PubMed ID: 20374979
[TBL] [Abstract][Full Text] [Related]
31. O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications.
Langen KJ; Hamacher K; Weckesser M; Floeth F; Stoffels G; Bauer D; Coenen HH; Pauleit D
Nucl Med Biol; 2006 Apr; 33(3):287-94. PubMed ID: 16631076
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and evaluation of O-(3-[18F]fluoropropyl)-L-tyrosine as an oncologic PET tracer.
Tang G; Wang M; Tang X; Luo L; Gan M
Nucl Med Biol; 2003 Oct; 30(7):733-9. PubMed ID: 14499331
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of 18F-fluoroethyl-L-tyrosine PET and MRI in small nonspecific incidental brain lesions.
Floeth FW; Sabel M; Stoffels G; Pauleit D; Hamacher K; Steiger HJ; Langen KJ
J Nucl Med; 2008 May; 49(5):730-7. PubMed ID: 18413396
[TBL] [Abstract][Full Text] [Related]
34. Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma.
Galldiks N; Stoffels G; Ruge MI; Rapp M; Sabel M; Reifenberger G; Erdem Z; Shah NJ; Fink GR; Coenen HH; Langen KJ
J Nucl Med; 2013 Dec; 54(12):2046-54. PubMed ID: 24159047
[TBL] [Abstract][Full Text] [Related]
35. Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis.
Dunet V; Pomoni A; Hottinger A; Nicod-Lalonde M; Prior JO
Neuro Oncol; 2016 Mar; 18(3):426-34. PubMed ID: 26243791
[TBL] [Abstract][Full Text] [Related]
36. Pilot Preclinical and Clinical Evaluation of (4S)-4-(3-[18F]Fluoropropyl)-L-Glutamate (18F-FSPG) for PET/CT Imaging of Intracranial Malignancies.
Mittra ES; Koglin N; Mosci C; Kumar M; Hoehne A; Keu KV; Iagaru AH; Mueller A; Berndt M; Bullich S; Friebe M; Schmitt-Willich H; Gekeler V; Fels LM; Bacher-Stier C; Moon DH; Chin FT; Stephens AW; Dinkelborg LM; Gambhir SS
PLoS One; 2016; 11(2):e0148628. PubMed ID: 26890637
[TBL] [Abstract][Full Text] [Related]
37. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.
Chen W; Silverman DH; Delaloye S; Czernin J; Kamdar N; Pope W; Satyamurthy N; Schiepers C; Cloughesy T
J Nucl Med; 2006 Jun; 47(6):904-11. PubMed ID: 16741298
[TBL] [Abstract][Full Text] [Related]
38. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma.
Pöpperl G; Goldbrunner R; Gildehaus FJ; Kreth FW; Tanner P; Holtmannspötter M; Tonn JC; Tatsch K
Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1018-25. PubMed ID: 15877226
[TBL] [Abstract][Full Text] [Related]
39. O-(2-[18F]fluoroethyl)-L-tyrosine (18F-FET) uptake in mouse thymoma cells, and its biodistribution in mice and human volunteers.
Abe K; Hayashi K; Sasaki M; Koga H; Kaneko K; Sawamoto H; Himuro K; Honda H
Acta Radiol; 2006 Dec; 47(10):1042-8. PubMed ID: 17135006
[TBL] [Abstract][Full Text] [Related]
40. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.
Hashimoto Y; Tsujikawa T; Kondo C; Maki M; Momose M; Nagai A; Ohnuki T; Nishikawa T; Kusakabe K
J Nucl Med; 2006 Mar; 47(3):426-31. PubMed ID: 16513611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
